DETAILS, FICTION AND CLINICAL EFFECTIVENESS OF ABBV-744 IN AML PATIENTS

In Phase A, members will obtain various doses and schedules of oral ABBV-744 tablet to recognize Secure dosing program. More individuals will likely be enrolled on the identified monotherapy dosign routine. In Section B, contributors will receive oral ruxolitinib and ABBV-744 will be offered as "add-on" therapy. In Section C, participants will acqu